Il nostro sito usa i cookie per una migliore fruibilità di navigazione ed effettuare statistiche sul suo utilizzo. Se vuoi saperne di più, o negare il consenso a tutti o ad alcuni cookie, clicca qui. Se prosegui nella navigazione sul sito acconsenti all'uso dei cookie.
10 giu 2019

Menarini Ricerche at the 24th EHA congress presenting the First In Human clinical study of SEL24/MEN1703

Pomezia, Italy, June 10th , 2019 – Menarini Ricerche will present at the 24th EHA Congress 2019 in Amsterdam on the First In Human clinical trial of SEL24/MEN1703 (DIAMOND-01, NCT03008187).

During the poster session dedicated to “Acute Myeloid Leukemia - Clinical” on June 14th 2019, 17:30PM- 19:00PM, the poster “CLI24-001: First-in-human study of SEL24/MEN1703, an oral dual PIM/FLT3 kinase inhibitor, in patients with acute myeloid leukemia” will be presented (Final Abstract Code: PF281).

This poster will report the study design of the FIH clinical trial DIAMOND-01 of SEL24/MEN1703, a molecule in-licensed from Selvita, in patients with newly diagnosed Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, and Primary Refractory Acute Myeloid Leukemia and no available therapeutic options (NCT03008187). The main objective of the study, conducted in the US, is the identification of the recommended phase 2 dose.

Menarini Ricerche is eager to present this study, which is the first trial testing a dual PIM/FLT3 inhibitor in AML. In addition, this is the first trial testing a dual PIM/FLT3 inhibitor with the potential to be a benefit for AML patients regardless of their FLT3 mutational status, and to overcome FLT3 inhibitor resistance.

The contribution of Menarini Ricerche to international conferences in Oncology, such as the EHA congress, is a key component of our commitment to developing new drugs for patients with difficult to treat cancers and poor prognosis.